Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
about
Bioresorbable vascular scaffolds technology: current use and future developmentsBioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricksThe Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic ReviewContemporary management of ST-segment elevation myocardial infarction.Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experienceClinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review.Current and future perspectives on drug-eluting bioresorbable coronary scaffolds.Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective."Leaving nothing behind": is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease?The year in cardiology 2014: coronary intervention.A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.Alternative stents in ST-segment elevation myocardial infarction: improving the efficacy of primary percutaneous coronary intervention.Absorb bioresorbable stents for the treatment of coronary artery disease.Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.Almanac 2015: coronary artery disease.Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study.Current and novel approaches to treat patients presenting with ST elevation myocardial infarction.Optimisation of percutaneous coronary intervention: indispensables for bioresorbable scaffolds.Bioresorbable vascular scaffolds - basic concepts and clinical outcome.IVUS-Guided Implantation of Bioresorbable Vascular Scaffolds for Very Late Paclitaxel Stent Thrombosis.Bioresorbable Vascular Scaffolds in a Real-World Patient Population-Results From a Mid-Term Angiographic Follow-Up.A 12-month angiographic and optical coherence tomography follow-up after bioresorbable vascular scaffold implantation in patients with ST-segment elevation myocardial infarction.Bioresorbable vascular scaffolds-time to vanish?Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions.Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions.Assessment of bioresorbable scaffold with a novel high-definition 60 MHz IVUS imaging system: Comparison with 40-MHz IVUS referenced to optical coherence tomography.Thirty-Day and One-Year Clinical Outcomes of Bioresorbable Vascular Scaffold Implantation: A Single-Center Experience.Bioresorbable Vascular Scaffold Korean Expert Panel Report.Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?The search for optimal dual antiplatelet therapy after PCI: fine-tuning of initiation and duration.Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy.Improving vessel healing with fully bioresorbable drug-eluting stents: more than a pipe dream?
P2860
Q26741147-2261F2CB-3A55-46EF-B0AB-9E9FEF413363Q26775130-CD4A4EEA-CCC0-4C11-A979-4E1DB5596A2FQ26782136-EA66C492-7342-4B6D-A03C-ED9FAE0EAE43Q34542192-AD65B885-807D-4426-B672-0780EC18E285Q35610359-148B009E-C415-4156-9244-CD87DB953865Q35787354-F9D0A32C-356A-465A-9D50-9973C76A4C65Q35884429-2ACE6D5A-49F2-44FB-8D2C-CCFD359199B5Q38224405-3F0AFB21-9A49-4A13-B28E-07A59F2B10CFQ38236449-0AD2F669-B663-4D57-BCB3-18D3F20BAAE4Q38285660-F1537449-E2B5-4EB6-B1DC-F5A9419E92D3Q38307432-8A1BABF3-48C8-4122-8C18-FDCF483BDB33Q38385959-1817384C-2535-4931-85AC-E3A0916B9EC6Q38506261-85181FA4-4A34-4BF5-A49C-B609B006063FQ38573540-F0A53043-0478-4733-8935-E9A4BBFE363CQ38592121-DCD0A8A8-CBA6-4401-9EB7-9A328B343401Q38714574-173448A2-8782-49EA-B7A8-957F2ADA7FE9Q38813631-11B9D988-9123-4A6C-AB25-4D0E81740E0DQ38855389-7B633DE8-6232-4983-906E-CD6D592F4FFDQ38885397-3EA1215D-680F-455C-96D8-1CF1F49FF3AFQ38967027-705F26E7-2BAF-4FA8-8DA7-A9E9A8DEBF28Q39140488-646A47A5-938E-48B4-BE72-3638402F8657Q39665517-A520D20A-E062-4011-86DB-66F1E31959A4Q40898662-B9BDB153-76EE-4D98-9435-7D8F8A107886Q41860479-3105F391-2F6A-4492-95A3-BC5449B18F6CQ41875719-CB3FE1EF-9A08-41F1-9851-A8ECFA8132DDQ42079506-5AED306F-AD2F-4DDC-BABD-FD77FFC5FC1CQ45953456-B42FB7D0-2CBA-41A7-9C85-2572B88A5AA5Q46228864-1E927DEE-0CC1-4872-A71F-40C05E724ACCQ46586855-F3D46F44-DF91-44BC-93AD-B878CA8B4C15Q47111093-1DF897FF-0251-4B24-A369-8C68CB91B5B6Q47131528-1416EF1F-F2F3-46CB-BA07-07EA319AEFD5Q47625273-BA1F2B06-AE70-4561-9C64-BDC3F6FF83A8Q47686997-C858EB24-9ADD-4243-9C38-0001EF0E056DQ51551532-1556388A-690C-4BC5-916E-C31C4340BFAAQ51664075-50217571-AD1D-4A6B-9D2D-652BE6A4C464Q51682621-D4240DCE-58D3-40EA-9FD8-733E34F17FEC
P2860
Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Everolimus-eluting bioresorbab ...... rction: BVS STEMI first study.
@en
Everolimus-eluting bioresorbab ...... rction: BVS STEMI first study.
@nl
type
label
Everolimus-eluting bioresorbab ...... rction: BVS STEMI first study.
@en
Everolimus-eluting bioresorbab ...... rction: BVS STEMI first study.
@nl
prefLabel
Everolimus-eluting bioresorbab ...... rction: BVS STEMI first study.
@en
Everolimus-eluting bioresorbab ...... rction: BVS STEMI first study.
@nl
P2093
P2860
P50
P356
P1476
Everolimus-eluting bioresorbab ...... rction: BVS STEMI first study.
@en
P2093
Evelyn Regar
Felix Zijlstra
Jurgen Ligthart
Mattie J Lenzen
Nicolas M Van Mieghem
Peter P de Jaegere
Robert Jan van Geuns
Roberto Diletti
Shimpei Nakatani
Sjoerd T Nauta
P2860
P304
P356
10.1093/EURHEARTJ/EHT546
P577
2014-01-06T00:00:00Z